Alto Neuroscience, Inc. (NYSE:ANRO) Receives $35.25 Consensus PT from Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been given an average rating of “Moderate Buy” by the eleven analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.25.

ANRO has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, July 29th. Wall Street Zen cut shares of Alto Neuroscience from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Wedbush lifted their target price on shares of Alto Neuroscience from $21.00 to $24.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a report on Wednesday, June 17th. Finally, Zacks Research cut shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd.

Institutional Trading of Alto Neuroscience

A number of institutional investors have recently modified their holdings of ANRO. AQR Capital Management LLC bought a new stake in shares of Alto Neuroscience in the first quarter worth about $52,000. Torren Management LLC bought a new position in Alto Neuroscience during the 4th quarter valued at approximately $62,000. Invesco Ltd. bought a new position in Alto Neuroscience during the 1st quarter valued at approximately $67,000. Bridgeway Capital Management LLC lifted its holdings in Alto Neuroscience by 85.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock worth $119,000 after buying an additional 25,000 shares during the period. Finally, Balyasny Asset Management L.P. purchased a new stake in Alto Neuroscience in the 4th quarter worth approximately $198,000.

Alto Neuroscience Stock Down 0.4%

ANRO opened at $28.12 on Monday. The company has a market cap of $986.91 million, a P/E ratio of -11.62 and a beta of 1.06. The business’s 50-day moving average price is $24.53 and its 200-day moving average price is $22.17. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 12 month low of $3.00 and a 12 month high of $28.85.

Alto Neuroscience (NYSE:ANRO) last released its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). On average, equities analysts expect that Alto Neuroscience will post -3.14 EPS for the current year.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.